A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly in Japanese Adult Patients With Advanced Solid Malignancies.
Latest Information Update: 17 Dec 2016
Price :
$35 *
At a glance
- Drugs AZD 4877 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 22 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 22 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Feb 2008 New trial record.